278 related articles for article (PubMed ID: 38162667)
1. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
[TBL] [Abstract][Full Text] [Related]
2. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
3. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
Abuhelwa Z; Alloghbi A; Nagasaka M
Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
Marks JA; Wilgucki M; Liu SV; Reuss JE
Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
[TBL] [Abstract][Full Text] [Related]
6. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
Marks S; Naidoo J
Lung Cancer; 2022 Jan; 163():59-68. PubMed ID: 34923203
[TBL] [Abstract][Full Text] [Related]
7. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
Chen X; Zeng C
Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
[TBL] [Abstract][Full Text] [Related]
8. A narrative review of antibody-drug conjugates in
Hsu R; Benjamin DJ
Front Oncol; 2023; 13():1252652. PubMed ID: 38107063
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
Reuss JE; Rosner S; Levy BP
Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
Riudavets M; Sullivan I; Abdayem P; Planchard D
ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
15. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
16. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
Reuss JE; Gosa L; Liu SV
Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab Deruxtecan in
Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
[TBL] [Abstract][Full Text] [Related]
18. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
19. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
Salifu I; Singh N; Berraondo M; Remon J; Salifu S; Severson E; Quintana A; Peiró S; Ramkissoon S; Vidal L; Chico I; Saini KS
Cancer Treat Res Commun; 2023; 36():100713. PubMed ID: 37172552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
